Related references
Note: Only part of the references are listed.Pharmacokinetics of the TRPV1 Antagonist ABT-102 in Healthy Human Volunteers: Population Analysis of Data From 3 Phase 1 Trials
Ahmed A. Othman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain
A. L. Krarup et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
Patrick Round et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Transient receptor potential channels as therapeutic targets
Magdalene M. Moran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial
Michael C. Rowbotham et al.
PAIN (2011)
Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway
Martin J. Gunthorpe et al.
DRUG DISCOVERY TODAY (2009)
Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia
Prisca Honore et al.
PAIN (2009)
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management
Arthur Gomtsyan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
(R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo
Carol S. Surowy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans
Narender R. Gavva et al.
PAIN (2008)
Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method
Andrew C. Hooker et al.
PHARMACEUTICAL RESEARCH (2007)
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade
Narender R. Gavva et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors
Alexandre A. Steiner et al.
JOURNAL OF NEUROSCIENCE (2007)
The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation
Narender R. Gavva et al.
JOURNAL OF NEUROSCIENCE (2007)
Cold-seeking behavior as a thermoregulatory strategy in systemic inflammation
Maria C. Almeida et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist
DM Swanson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Lipopolysaccharide fever is initiated via a capsaicin-sensitive mechanism independent of the subtype-1 vanilloid receptor
MD Dogan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Vanilloid receptors take a TRP beyond the sensory afferent
MJ Caterina
PAIN (2003)
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
SM Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition
HH Chuang et al.
NATURE (2001)
The vanilloid receptor: A molecular gateway to the pain pathway
MJ Caterina et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
Impaired nociception and pain sensation in mice lacking the capsaicin receptor
MJ Caterina et al.
SCIENCE (2000)
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
D Smart et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)